<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533308</url>
  </required_header>
  <id_info>
    <org_study_id>NMSC-02-20</org_study_id>
    <nct_id>NCT04533308</nct_id>
  </id_info>
  <brief_title>The Impact of Virtual Reality on the Emotional State of Patients With Aphasia During Rehabilitation.</brief_title>
  <official_title>The Impact of Virtual Reality on the Emotional State of Patients With Aphasia During Rehabilitation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine virtual reality (VR) impact during standard program of&#xD;
      rehabilitation on emotional state of patients with aphasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: To test the safety of virtual reality in a vulnerable population of patients with&#xD;
      aphasia during rehabilitation. Participants will be alternately assigned to receiving a&#xD;
      relaxation session in VR every working day during a standard course of rehabilitation.&#xD;
&#xD;
      Aim 2: To test the preliminary efficacy of combining VR with the course of rehabilitation to&#xD;
      promote emotional improvements in patients with aphasia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absence of severe adverse reactions</measure>
    <time_frame>From admission to discharge, up to 3 weeks</time_frame>
    <description>Assessed by a self-reported form and physiological parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>10 - Stroke Aphasic Depression Questionnaire (SADQH-10)</measure>
    <time_frame>From admission to discharge, up to 3 weeks</time_frame>
    <description>Scores range from 0 to 30 with lower scores denoting better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Mood Scale (VAMS)</measure>
    <time_frame>From admission to discharge, up to 3 weeks</time_frame>
    <description>Scores range from 0 to 10 with lower scores denoting better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Scale (PSS)</measure>
    <time_frame>From admission to discharge, up to 3 weeks</time_frame>
    <description>Scores range from 0 to 50 with lower scores denoting better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-level European quality of life five-dimensional questionnaire</measure>
    <time_frame>From admission to discharge, up to 3 weeks</time_frame>
    <description>There are five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. Patients choice results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describe the health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aphasic Depression Rating Scale (ADRS)</measure>
    <time_frame>From admission to discharge, up to 3 weeks</time_frame>
    <description>Scores range from 0 to 36 with lower scores denoting better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lüscher Color Test</measure>
    <time_frame>From admission to discharge, up to 3 weeks</time_frame>
    <description>Eight different colored cards are place in order of preference. The descriptive statements formed by Lüscher for each color were used to interpret the results.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aphasia</condition>
  <condition>Virtual Reality</condition>
  <condition>Emotional Disturbances</condition>
  <arm_group>
    <arm_group_label>VR intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have a session in VR for 20-30 minutes each working day. They can choose natural 360-degrees scenes from different locations in the world with or without interactions with animals. The equipment will include HTC Vive (HTC Corporation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group will not receive any psychological interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relaxation in virtual reality</intervention_name>
    <description>Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality</description>
    <arm_group_label>VR intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild or moderate aphasia of any type&#xD;
&#xD;
          -  Russian is primary language&#xD;
&#xD;
          -  At least 2 weeks post cardio-vascular accident (ischemic or hemorrhagic stroke) or&#xD;
             head injury of any location&#xD;
&#xD;
          -  Have a history of only one stroke&#xD;
&#xD;
          -  Medically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Associated severe cognitive deficits and psychiatric disorders which prevent patients&#xD;
             understanding of the informed consent&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Medical history of severe visual or hearing impairment&#xD;
&#xD;
          -  Comorbid neurological diagnosis (e.g. epilepsy, multiple sclerosis, Parkinson disease,&#xD;
             dementia)&#xD;
&#xD;
          -  Unable to perform the required exercises due to severe motor, sensory or cognitive&#xD;
             deficit (memory, attention, executive functioning, apraxia, regulatory and planning&#xD;
             activities etc.) and medical problems (for example, anyone meeting New York Heart&#xD;
             Association Class IV criteria, hospitalization for myocardial infarction or heart&#xD;
             surgery within 120 days, severe cardiomyopathy or documented serious and unstable&#xD;
             cardiac arrhythmias)&#xD;
&#xD;
          -  Drug or alcohol addiction within the last 6 months.&#xD;
&#xD;
          -  Significant current psychiatric illness defined as affective disorder unresponsive to&#xD;
             medication or bipolar affective disorder, psychosis, schizophrenia or suicidality&#xD;
&#xD;
          -  Current participation in another interventional trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vadim D Daminov, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pirogov National Medical and Surgical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduard V Novak, MD, MSc</last_name>
    <phone>+74994641263</phone>
    <email>novakev@pirogov-center.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia I Slepnyova, MD</last_name>
    <phone>+74994642354</phone>
    <email>slepnyovani@pirogov-center.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pirogov National Medical and Surgical Center</name>
      <address>
        <city>Moscow</city>
        <zip>105037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard V Novak, MD, MSc</last_name>
      <phone>+74994641263</phone>
      <email>novakev@pirogov-center.ru</email>
    </contact>
    <contact_backup>
      <last_name>Natalia I Slepnyova, MD</last_name>
      <phone>+74994642354</phone>
      <email>slepnyovani@pirogov-center.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Eduard V Novak, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia I Slepnyova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</investigator_affiliation>
    <investigator_full_name>Eduard Novak</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Affective Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year after completion of the trial</ipd_time_frame>
    <ipd_access_criteria>upon request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

